A Multicenter, Open Label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005% in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis

Main Article Content

Adelaide A Herbert
Debbie Glaab
Rhonda Schreiber


Psoriasis, Calcipotriene, Corticosteroid, Halobetasol


Abstract not available.


1. National Psoriasis Foundation 2019 July 31 About Psoriasis Retrieved from Psoriasis Org www psoriasis org/parents/about psoriasis

2. Silverberg, N B 2009 Pediatric Psoriasis An Update Therapeutics and Clinical Risk Management, 5 849-856

3. Kimball, A Gold, M Zib B Davis, M Clobetasol Propionate Emulsion Formulation Foam Ph 2008 Clobetasol propionate emulsion formulation foam 0 05 review of phase II open label and phase III randomized controlled trials in steroid responsive dermatoses in adults and adolescents JAAD, 59 3 448 454

4. Shah, K N 2013 Diagnosis and Treatment of Pediatric Psoriasis Current and Future American Journal of Clinical Dermatology, 14 195

5. Wolverton S E 2001 Comprehensive Dermatologic Drug Therapy XlX ed Philadelphia, PA Saunders

6 Feldman S R Mills, M Brundage, T Eastman, W J 2013 March) A multicenter, randomized, double blind study of the efficacy and safety of calcipotriene foam, 0 005 vs vehicle foam in the treatment of plaque type psoriasis of the scalp JDD, 12 3 300 306

7 Hebert, A Glaab, D Schrieber R 2019 A Phase 1 Open Label Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0 005 Applied Under Maximum Use Conditions in Adolescent Subjects with Plaque Psoriasis SKIN The Journal of Cutaneous Medicine, 3 2

Most read articles by the same author(s)

1 2 > >>